Navigation Links
Microbicide trial results a turning point for HIV prevention, says team testing same gel
Date:7/19/2010

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

CAPRISA 004 involved 889 women from Durban and a nearby rural community in South Africa, where women are at especially high risk of acquiring HIV through sexual intercourse. Women were randomly assigned to one of two study groups tenofovir gel or placebo gel with no active ingredient and instructed to use the study product in a regimen timed before and after sex. At the end of the study, there were 39 percent fewer HIV infections among women who used tenofovir gel before and after sex than among those who used the placebo gel. The study was conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA).

"This study has established proof of concept that a vaginal microbicide containing an ARV can protect women from HIV. This is an incredibly important achievement for which the CAPRISA team is to be congratulated. For all of us in the HIV prevention field, this result has shown that it may be possible to leverage this initial success using a single ARV at the time of sex into more potent approaches that could be 50, 60 or even 70 percent effective for prevention of HIV. The results of this study have reinvigorated the field," commented Sharon Hillier, Ph.D., professor and vice chair for faculty affairs, and director of reproductive infectious disease research in the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine, and principal investigator of the Microbicide Trials Network (MTN).

The MTN currently is conducting another stu
'/>"/>

Contact: Lisa Rossi
rossil@upmc.edu
412-916-3315
Microbicide Trials Network
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
2. Study of microbicide gel shows reduced risk of HIV and herpes infections in women
3. Pregnancy doubles HIV risk in men; first trial of a microbicide in pregnant women
4. Press briefings at International Microbicides Conference May 22-25
5. Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials
6. BioSTARTM device achieves 90 percent closure rate for atrial septal defect in children
7. Hopkins faculty lead development of report to FDA on ethical, scientific issues related to post-market clinical trials
8. FDA Reviewer Questions Results of Key Avandia Trial
9. NOSCAR announces first NOTES transoral and transvaginal gallbladder removals performed as part of US multicenter human trial
10. University at Buffalo launches clinical trial of new multiple sclerosis treatment
11. Announcing: Intrinsic Imaging : Radiology Experts Launch Novel Medical Imaging CRO for Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... California (PRWEB) October 01, 2014 ... to benefit a very special cause. The campaign—“Buy ... support for Paws for Veterans, a nonprofit organization ... while also rescuing shelter dogs that would otherwise ... of featured products will support monthly donations of ...
(Date:10/1/2014)... October 01, 2014 Woodland Hills ... to a group of dental specialists who treat full ... Spain city of Oviedo. Dr. Reshad of the Anacapa ... with clients on two continents, will give a full-day ... full mouth reconstruction. , “These specialists want to improve ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Today ... the Anacapa Dental Art Institute in Oxnard and Woodland ... Bangalore providing full mouth rehabilitation training. , “Speaking to ... of these transformative procedures to get the help and ... rehabilitation may involve repairing previous dental work, providing cosmetic ...
(Date:10/1/2014)... DC (PRWEB) October 01, 2014 Generic ... all retail generics increasing in price in the last ... Services, Inc.’s (AIS) Drug Benefit News (DBN) interviewed a ... trend means for pharmacies and health plans. , ... with rising generic acquisition costs, these cost increases squeeze ...
(Date:10/1/2014)... Madison, Wi (PRWEB) October 01, 2014 ... sales of UP4 WOMEN’S probiotic to The National Network ... month of October. This organization was chosen through nationwide ... UP4’s website and social media outlets. , “We ... to receive a portion of every sale of UP4 ...
Breaking Medicine News(10 mins):Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2
... 2008 Use of the drug interferon as a ... disease associated with the hepatitis C virus is ineffective, ... nine other institutions have found in a multicenter study. ... (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear ...
... Corporation (NYSE: GTS ) today announced that it ... managed care assets of La Cruz,Azul de Puerto Rico, ... Association to transfer the licensing rights to the Blue Cross ... brands in the US Virgin Islands,to the Company and Triple-S, ...
... Available from NetLearning , ... Clifton ... leading provider of integrated e-learning solutions for healthcare training, compliance, ... pleased to announce the latest major release of the Learning ...
... medication used for high blood pressure does not improve ... results from a large, international study. , The ... Medical Center in key leadership positions, appears in this ... Medicine , published today. , The findings are disappointing ...
... finds , , THURSDAY, Dec. 4 (HealthDay News) -- Reactions ... are rare, and young women can tolerate subsequent doses. ... data after more than 380,000 doses of the Gardasil ... in April 2007. , Gardasil protects against four ...
... of Steven Sabock, a 50-year-old man with bipolar disorder who ... psychiatric institution after he choked on medication -- while, ... has focused attention on the crisis in North Carolina,s mental ... tragic, preventable death of Steven Sabock -- which made headlines ...
Cached Medicine News:Health News:HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective 2Health News:Triple-S Management Corporation Signs Letter of Intent to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc. 2Health News:NetLearning Releases Learning Administrator 7.1 for Online Professional Healthcare Training 2Health News:NetLearning Releases Learning Administrator 7.1 for Online Professional Healthcare Training 3Health News:Study finds treatment fails to improve common form of heart failure 2Health News:Study finds treatment fails to improve common form of heart failure 3Health News:Cervical Cancer Vaccine Well Tolerated 2Health News:Tragedy Focuses Spotlight on Crisis in North Carolina Mental Health System 2
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
(Date:10/1/2014)... October 1, 2014 Sophia Genetics, ... Sequencing (NGS) data analysis, today launches a unique CFTR ... analysis in a single NGS experiment. The CE-IVD marked ... of variants in a single NGS experiment with clinical ... not been possible to simultaneously analyse all relevant CFTR ...
(Date:9/30/2014)... , Sept. 30, 2014  Wrightington, Wigan ... Allscripts (NASDAQ: MDRX ) are delighted to ... as WWL,s new health information system. The system will ... completely transform the way WWL delivers healthcare in the ... a demonstrated record of on-time and on-budget system implementations ...
Breaking Medicine Technology:Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
... /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... largest drugstore chain in China based on the number ... will report its third quarter 2010 financial results on ... The Company will host a conference call, to ...
... Tibotec Announced Week 24 Interim Results From Phase... -- HUDDINGE, Sweden, November 1, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:China Nepstar Chain Drugstore to Report Third Quarter 2010 Financial Results on November 17, 2010 2Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 2Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 3Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 4Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 5Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 6Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 7Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 8Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 9Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 10Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 11Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 12Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD 13
Full Handle Laseredge Implant Blade Knife, 4.0 mm straight. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
Medicine Products: